Business Wire

ESI-GROUP

5.10.2021 08:02:16 CEST | Business Wire | Press release

Share
ESI 3-Year Strategic Plan “OneESI 2024 – Focus to Grow”

Regulatory News:

ESI Group (ISIN Code: FR0004110310, Symbol: ESI) announces its 3-year strategic plan focused on improving ESI Group’s topline and profitability. This plan will be presented and commented on Tuesday, October 5th , at 3:30pm CET during an Investor Conference.

Cristel du Rouvray, Chief Executive Officer of ESI Group says : "This 3-year plan will enable us to focus where we deliver the most value and therefore drive growth and profit for ESI that benefits all our stakeholders. This plan is an important milestone for our company, and it mobilizes the talent and energy of my entire team. I am very proud to lead a diverse team and I’m really confident that together we can achieve the expected result.”

ESI’s performance is a paradox: ESI is a key technology provider operating in a vibrant market and yet profit and growth are far below comparable and stakeholder expectations. ESI’s management believes that to unleash its potential:

  • ESI must focus on its core business to invest to win in key simulation markets;
  • ESI must globalize its distribution to serve global customers, including a globally coordinated value packaging & pricing strategy.

The Group spent the past 7 months developing this “OneESI 2024 - Focus to Grow” plan to focus on the core business and globalize operations; in recent months, management spent time explaining to an extended team of key leaders the necessity and the credibility of this plan. ESI is now entering the next phase of communicating more broadly and executing on all facets of this transformation.

Financial ambitions for 2024

To increase its competitiveness, ESI must focus to grow. The Group has already made significant progress in this direction, as communicated during its H1-FY21 results, thanks to its healthy run rate initiative, the group posted both a growth in revenue and an improvement in profitability, and in tandem a sustained reduction in headcount and costs in the past year. The Group expects to continue with this trajectory, estimating a further reduction in headcount of approximately 5% by Dec 2022 and then a stabilization of headcount. This reorganization will be implemented in the various regions of the Group in accordance with the legal rules applicable to each of them.

Accelerating in this direction, the Group announces its 2024 financial objectives. With its plan “OneESI 2024 – Focus to grow”, ESI aims to reach:

  • A high single digit growth
  • an adjusted EBIT to exceed 20%

At constant exchange rate

2022

2023

2024

Revenue
(adjusted for
special projects1 )

4% - 6%

6% - 8%

7% - 9%

Adjusted EBIT2

10% - 12%

15% - 17%

20% - 22%

To achieve this plan, ESI counts on its key levers:

  • a confirmed opportunity in a growing and vibrant simulation market
  • a renewed operating model
  • a best-in-class governance
  • committed teams

By building off its accelerators, the management ambitions a higher growth beyond this 3-year horizon.

More details

To present its “OneESI 2024 – Focus to grow” plan, ESI is organizing an Investor Conference which will be held on Tuesday, October 5th , 2021 at 3:30pm CET. To access it, click HERE .

Upcoming events

  • Q3 revenues – October 28th , 2021
  • FY21 sales and results - February 28th , 2022

Forward-looking Statements

This release contains “forward-looking statements”. These statements are subject to a number of risks and uncertainties, including those related to the COVID-19 virus and associated further economic and market disruptions; further adverse changes or fluctuations in the global economy; further adverse fluctuations in our industry, foreign exchange fluctuations, changes in the current global trade regulatory environment; fluctuations in customer demands and markets; fluctuations in demand for our products including orders from our large customers; cyber-attacks; expense overruns; and adverse effects of price changes or effective tax rates. The company directs readers to its Universal Registration Document – Chapter 3 presenting the risks associated with the company’s future performance.

About ESI Group

Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time, while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval, energy and heavy industry, ESI is present in more than 20 countries, employs 1200 people around the world and reported 2020 sales of €132.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.

For further information, go to www.esi-group.com .

Follow ESI

http://www.esi-group.com/linkedin
http://www.esi-group.com/facebook
http://www.esi-group.com/twitter
http://www.esi-group.com/youtube

_______________________
1
For the 3-year plan, the growth of revenue excludes special projects
2 Operational income – our EBIT – is adjusted for IFRS standard on leases, amortization of intangible assets related to acquisitions, stock-based compensation expense and restructuring charges

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Advances Operational Orchestration Vision with Agentic AI at Kinexions EMEA 202615.9.2026 13:00:00 CEST | Press release

Global brands including Bosch, Castrol, Coca-Cola Al Ahlia Beverages, and Moët Hennessy take the stage in Barcelona as Kinaxis sets the direction for the next era of supply chain Kinaxis® Inc. (TSX:KXS), a global leader in AI-powered supply chain planning and orchestration, will bring together some of the world’s most innovative supply chain leaders at Kinexions EMEA 2026 from October 26-28. Building on the operational orchestration vision Kinaxis introduced earlier this year, the conference offers an inside look at how leading organizations are harnessing AI innovation and agentic capabilities to help supply chain leaders make better decisions, coordinate action across the business and drive measurable outcomes. From AI Potential to Operational Impact As organizations continue to invest heavily in AI, many struggle to translate intelligence into action - just 12% of supply chain leaders consider themselves AI leaders, despite widespread deployment of AI capabilities. Kinaxis CEO Razat

Cebreo Medical Receives CE Mark for NeuroBuds®, a Discreet In-Ear, Medical-Grade EEG Wearable for Extended Ambulatory Monitoring15.9.2026 13:00:00 CEST | Press release

The Danish medtech company's ear-EEG platform can now be placed on the European market, enabling clinicians to record multi-day and multi-night EEG in the patient's home for epilepsy, sleep and other neurophysiological research and care. Cebreo Medical today announced that its NeuroBuds® device has received CE marking, confirming conformity with applicable EU requirements. Unlike conventional EEG systems that require a technician-applied cap of electrodes, NeuroBuds is designed to be used unassisted by the patient at home, enabling multi-day and multi-night recordings in a patient's daily life environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914704547/en/ NeuroBuds(TM), EarEEG “With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients’ own homes. The product has the potential to significantly reduce the cost of long-term EEG monitoring

Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 12:30:00 CEST | Press release

New U.S. healthcare provider (HCP) disease education initiative, Change the Tunein TRD explores the neurobiology and care pathways to support greater recognition and understanding of treatment-resistant depression (TRD)​ TRD occurs when people with major depressive disorder (MDD) are failed by at least two different antidepressant treatment regimens of adequate dose, duration and adherence in the same episode Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated

NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 12:00:00 CEST | Press release

Building on NIQ's GeoPurchase capabilities, the new solution extends geographic purchase intelligence into digital-first categories across Europe NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these sig

QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 12:00:00 CEST | Press release

Multi-program collaboration leveraging QurCan’s TERP™ polymer-lipid nanoparticle delivery platformLilly to make a strategic investment in QurCan QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboratio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye